The global progressive multifocal leukoencephalopathy treatment market is expected to garner a market value of USD 1,320 million in 2023 and is expected to accumulate a market value of USD 1,773.97 million by registering a CAGR of 3% in the forecast period 2023 to 2033. The market for progressive multifocal leukoencephalopathy treatment registered a CAGR of 2% in the historical period 2018 to 2022.
The progressive multifocal leukoencephalopathy treatment market is a segment of the healthcare industry that deals with the effective management of the condition. The progressive multifocal leukoencephalopathy treatment market offers a range of products and services for its effective management and treatment such as corticosteroids, such as prednisone, antiviral medications, such as cidofovir, Immunoglobulin therapy, and immunomodulatory treatments, such as interferon.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | USD 1,320 million |
| Anticipated Forecast Value (2033) | USD 1,773.97 million |
| Projected Growth Rate (2023 to 2033) | 3% CAGR |
According to market research and competitive intelligence provider, Future Market Insights- the market for progressive multifocal leukoencephalopathy treatment reflected a value of 2% during the historical period, 2018 to 2022.
The market for Progressive Multifocal Leukoencephalopathy Treatment is gaining prominence as it is considered a rare, life-threatening brain disease caused by the JC virus. Furthermore, due to the rarity of the disease, there is ongoing research into developing new treatments for PML, expected to drive demand for these treatments.
The development of new PML treatments is a high priority for the medical community due to the devastating effects of the disease and the limited treatment options available. As more effective treatments become available, the market for PML treatment is likely to grow. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of Progressive Multifocal Leukoencephalopathy Treatments is fuelling the market growth. Thus, the market for progressive multifocal leukoencephalopathy treatment is expected to register a CAGR of 3% in the forecast period 2023 to 2033.
Growing advancements in diagnostic and treatment options to push the market growth
The global market for progressive multifocal leukoencephalopathy treatment is primarily driven by the incidence of blood cancers, including multiple myeloma, the development of new and effective treatment options, advancements in treatment technologies and development of new diagnostic technologies and the availability of more effective treatments. According to the latest studies, PML occurs in approximately one in 200,000 people. As per the same report, each year, it is estimated that 4,000 people develop PML in the United States and Europe combined.
The growth of the progressive multifocal leukoencephalopathy treatment market is owed to the increasing prevalence of the condition owing to the increasing use of immunosuppressive drugs for autoimmune and other conditions. As a result, the players in the market are working on the development of new diagnostic tools and imaging techniques that are likely to improve the accuracy of Progressive Multifocal Leukoencephalopathy diagnosis.
For instance, in November 2021, Japan approved the world's first oncolytic virus-based immunotherapy called Teserpaturev, bringing new hope to individuals struggling with a malignant brain tumor known as GBM. Teserpaturev is a genetically engineered herpes simplex virus type 1 (HSV-1) that boasts a unique capability of not only killing the brain tumor cells it infects, but also those that have spread to other parts of the brain. This is achieved by activating a patient's own immune system to fight the tumor.
Expensive Cost of Treatment to restrict Market Growth
The market is projected to get significantly affected by the challenging factors such as limited availability and high cost of advanced Progressive Multifocal Leukoencephalopathy Treatment options. Expensive treatments and related costs such as hospitalization, intensive care, or specialized diagnostic tests, is expected to hinder the market growth. Furthermore, poor healthcare infrastructure, especially in developing countries, can limit access to Progressive Multifocal Leukoencephalopathy Treatment and the availability of diagnostic and therapeutic options.
Improvement in healthcare spending propelling growth of the regional markets
The South and East Asia is expected to exhibit the significant growth rate of all regions over the forecast period, with a share of 20% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the progressive multifocal leukoencephalopathy treatment in the region.
South Asia is an emerging market due to the increase in point of care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the market worldwide.
Increasing Prevalence of Skin Conditions Shaping Landscape for Progressive Multifocal Leukoencephalopathy Treatment in North America
North America is anticipated to acquire a market share of about 40% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region along with the high healthcare expenditure and a large geriatric population.
The United States of America holds the highest share in the North American market, followed by Canada. Presence of a large number of pharmaceutical companies, which are investing heavily in the development of new, targeted treatments for the condition, high level of healthcare expenditure and the high incidence of PML leading to a large patient population are some of the factors responsible for the growth of the market in the region.
Rising prevalence of HIV infection to push market growth
According to the studies, 38 million people worldwide are currently living with HIV or AIDS. The increasing incidence of HIV infection in many middle- and low-income countries is projected to drive the growth of the market for progressive multifocal leukoencephalopathy treatment over the forecast period.
Favorable reimbursement policies for both HIV and cancer treatment are expected to further drive the growth of the progressive multifocal leukoencephalopathy market over the forecast period.
Hospital pharmacies to take the lead and drive market growth
According to the FMI analysis, Hospital pharmacy accounts for the largest market share. The requirement for several hospital stays and visits during the progressive multifocal leukoencephalopathy treatment facilitates the growth of this segment. The majority of the serious venous diseases involving the brain are treated in hospitals, and with the availability of trained medical personnel, it is simpler to control an individual's health more correctly.
Key players in the market include pharmaceutical companies such as NeoImmuneTech, Neurimmune, GlaxoSmithKline Plc, Sanofi S.A., Gilead Sciences, Inc., Allergan Plc., Novartis AG, AbbVie Inc., and Bristol-Myers Squibb Company along with healthcare providers and technology companies among other global players.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 1,320 million |
| Market Value in 2033 | USD 1,773.97 million |
| Growth Rate | CAGR of 3% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Treatment, Indication, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | NeoImmuneTech; Inhibikase Therapeutics; Neurimmune; Pfizer Inc.; GSK Plc; Sanofi S.A.; Gilead Sciences Inc.; Allergan Plc.; Novartis AG; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Bristol-Myers Squibb Company |
| Customization | Available Upon Request |
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 15: Europe Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: South Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 19: South Asia Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 20: South Asia Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: East Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 23: East Asia Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 24: East Asia Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: Oceania Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 27: Oceania Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 28: Oceania Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 30: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 31: MEA Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 32: MEA Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Indication, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 17: Global Market Attractiveness by Treatment, 2023 to 2033
Figure 18: Global Market Attractiveness by Indication, 2023 to 2033
Figure 19: Global Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Indication, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 37: North America Market Attractiveness by Treatment, 2023 to 2033
Figure 38: North America Market Attractiveness by Indication, 2023 to 2033
Figure 39: North America Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Indication, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 57: Latin America Market Attractiveness by Treatment, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Indication, 2023 to 2033
Figure 59: Latin America Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Europe Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 62: Europe Market Value (US$ Million) by Indication, 2023 to 2033
Figure 63: Europe Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 71: Europe Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 77: Europe Market Attractiveness by Treatment, 2023 to 2033
Figure 78: Europe Market Attractiveness by Indication, 2023 to 2033
Figure 79: Europe Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 80: Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: South Asia Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 82: South Asia Market Value (US$ Million) by Indication, 2023 to 2033
Figure 83: South Asia Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: South Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 89: South Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 91: South Asia Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 92: South Asia Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 94: South Asia Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 95: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 96: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 97: South Asia Market Attractiveness by Treatment, 2023 to 2033
Figure 98: South Asia Market Attractiveness by Indication, 2023 to 2033
Figure 99: South Asia Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 101: East Asia Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 102: East Asia Market Value (US$ Million) by Indication, 2023 to 2033
Figure 103: East Asia Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: East Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 109: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 111: East Asia Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 112: East Asia Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 114: East Asia Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 115: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 116: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 117: East Asia Market Attractiveness by Treatment, 2023 to 2033
Figure 118: East Asia Market Attractiveness by Indication, 2023 to 2033
Figure 119: East Asia Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 121: Oceania Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 122: Oceania Market Value (US$ Million) by Indication, 2023 to 2033
Figure 123: Oceania Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: Oceania Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 129: Oceania Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 131: Oceania Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 132: Oceania Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 134: Oceania Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 135: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 137: Oceania Market Attractiveness by Treatment, 2023 to 2033
Figure 138: Oceania Market Attractiveness by Indication, 2023 to 2033
Figure 139: Oceania Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 141: MEA Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 142: MEA Market Value (US$ Million) by Indication, 2023 to 2033
Figure 143: MEA Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 148: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 149: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 150: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 151: MEA Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 152: MEA Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 153: MEA Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 154: MEA Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 155: MEA Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 156: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 157: MEA Market Attractiveness by Treatment, 2023 to 2033
Figure 158: MEA Market Attractiveness by Indication, 2023 to 2033
Figure 159: MEA Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 160: MEA Market Attractiveness by Country, 2023 to 2033
The market in 2023 is valued at USD 1,320 million.
The market rose at a 2% CAGR from 2018 to 2022.
Until 2033, the market will experience a 3% CAGR.
The market shall reach USD 1,773.97 million in 2033.
North America is likely to generate 40% revenue in 2023.
Explore Therapy Area Insights
Progressive Multifocal Leukoencephalopathy Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
